Almirall SA operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Almirall SA with three other
pharmaceutical manufacturers in Europe:
of the United Kingdom
sales of £664.95 million [US$816.89 million]
of which 100%
was Buprenorphine Based Drugs),
(607.80 million Euro [US$667.18 million]
of which 51%
was Non-Proprietary Homeopathic Medicines), and
based in Russia
(47.19 billion Russian Rubles [US$757.48 million]
of which 97%
was Pharmaceutical Products OTC).
Almirall SA reported sales of 684.99 million Euro (US$751.90 million)
December of 2015.
decrease of 12.9%
versus 2014, when the company's sales were 786.40 million Euro.
Contributing to the drop in overall sales was the 58.9% decline
in Licenses, from 97.56 million Euro to 40.13 million Euro.
There were also decreases in sales in
Own Network (Spain) (down 16.3% to 472.05 million Euro)
However, these declines were partially offset by the increase in sales of
Dermatology (up 35.4% to 150.01 million Euro)
Corporate (up 64.4% to 22.79 million Euro)